On Friday, January 31 Novartis will announce its Q4 and Full-Year 2024 results. Register to listen here: t.co/qRmJZD5Y8k#NovartisNews $NVS $NOVN #NVSQ424
Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance.
#NovartisNews $NVS $NOVN #NVSQ323
Breaking News: Novartis announces intention to separate Sandoz business to create a standalone company.
Planned 100% spin-off provides potential future upside of both Sandoz and Novartis Innovative Medicines.
#NovartisNews $NVS $NOVN